Earnings impact of revisions to dispensing fees and drug prices
First written in FY2016. 19 of 21 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 4 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The Group is seeking to mitigate this risk by strengthening initiatives involving claims for dispensing technical fees and pharmaceutical management fees, but if dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It continues to identify the risk of revisions to dispensing fees and drug prices and cites strengthening initiatives involving claims for dispensing technical fees and pharmaceutical management fees as risk mitigation measures. - FY2025RestatedAnnual report
「The Group is seeking to mitigate this risk by strengthening initiatives involving claims for dispensing technical fees and pharmaceutical management fees, but if dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It continues to identify the risk of revisions to dispensing fees and drug prices and cites strengthening initiatives involving claims for dispensing technical fees and pharmaceutical management fees as risk mitigation measures. - FY2024-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes to the existing business and other risks, including the impact on earnings from revisions to dispensing fees and drug prices. - FY2022RestatedAnnual report
「The Group is seeking to mitigate this risk by strengthening initiatives involving generic drugs and claims for pharmaceutical management fees, but if dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It continues to identify the risk of revisions to dispensing fees and drug prices and cites strengthening initiatives involving generic drugs and claims for pharmaceutical management fees as risk mitigation measures. - FY2022-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2022-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2021MitigatedAnnual report
「The Group is seeking to mitigate this risk by strengthening initiatives to claim pharmaceutical management fees for generic drugs, but if dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It expressly identifies strengthening initiatives to claim pharmaceutical management fees for generic drugs as a risk mitigation measure against the risk of revisions to dispensing fees and drug prices. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2021-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2020-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2020-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2020-Q1RestatedAnnual report
「During the three-month period ended June 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2019RestatedAnnual report
「If dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It continues to identify the impact on dispensing revenue from revisions to dispensing fees and drug prices as a risk. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2019-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2019-Q1RestatedAnnual report
「During the three-month period ended June 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2018RestatedAnnual report
「If dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It continues to identify the impact on dispensing revenue from revisions to dispensing fees and drug prices as a risk. - FY2018-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2018-Q2RestatedAnnual report
「During the six-month period ended September 30, there were no new business risks or material changes to the business risks described in the securities report for the previous fiscal year.」
It states that there have been no material changes regarding the impact on earnings from revisions to dispensing fees and drug prices. - FY2017RestatedAnnual report
「If dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It continues to identify the impact on earnings from revisions to dispensing fees and drug prices as a risk. - FY2016First statedAnnual report
「If dispensing fees and drug prices are revised in the future and points or other items are changed, this could affect the Group's results.」
It identifies system revisions driven by efforts to control national medical expenditure as an external risk to dispensing revenue.